Work at Blacksmith Medicines Inc. has led to the identification of new bacterial UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors reported to be useful for the treatment of Pseudomonas aeruginosa infection, lung diseases and infectious pneumonia.
A Chong Kun Dang Pharmaceutical Corp. patent describes new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors potentially useful for the treatment of cancer, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, ulcerative colitis, graft-vs.-host disease, systemic lupus erythematosus and osteoarthritis, among others.
Oregon Health & Science University and Washington University have jointly developed new tetrahydrobenzothiophene and tetrahydropyridothiophene derivatives reported to be useful for the treatment of flavivirus and alphavirus infections.
Recurium IP Holdings LLC has patented new Wee1-like protein kinase (Wee1) inhibitors and/or degradation inducers reported to be useful for the treatment of cancer.
Investigators at the University of Texas have synthesized new mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) and Bruton tyrosine kinase (BTK) dual-target inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Otsuka Pharmaceutical Co. Ltd. has identified new piperidine- and morpholine-carboxylate compounds acting as sortilin (SORT; NT3; Gp95) antagonists. As such, they are described as potentially useful for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer’s and Parkinson’s disease.
A Juno Therapeutics Inc. patent describes pyrazole-based DNA-dependent protein kinase (DNA-PK) inhibitors reported to be useful for the treatment of cancer.
Several French institutions, including the University of Rennes, have prepared and tested disubstituted ferrocene complexes acting as viral replication inhibitors reported to be useful for the treatment of viral infections.
RSS